- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Filgotinib: First Approval ; volume:81 ; number:2 ; day:2 ; month:2 ; year:2021 ; pages:297 ; date:2.2021
Drugs ; 81, Heft 2 (2.2.2021), 297, 2.2021
- Urheber
-
Dhillon, Sohita
Keam, Susan J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-021-01468-3
- URN
-
urn:nbn:de:101:1-2021041813401239863437
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dhillon, Sohita
- Keam, Susan J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Lenacapavir: First Approval
Correction to: Nedosiran: First Approval
Correction to: Triheptanoin: First Approval
Correction to: Ritlecitinib: First Approval
Correction to: Zavegepant: First Approval
Correction to: Sotorasib: First Approval
Correction to: Inclisiran: First Approval
Correction to: Tralokinumab: First Approval
Correction to: Spesolimab: First Approval
Correction to: Ubrogepant: First Approval
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Lenacapavir: First Approval
Correction to: Nedosiran: First Approval
Correction to: Triheptanoin: First Approval
Correction to: Ritlecitinib: First Approval
Correction to: Zavegepant: First Approval
Correction to: Sotorasib: First Approval
Correction to: Inclisiran: First Approval
Correction to: Tralokinumab: First Approval
Correction to: Spesolimab: First Approval
Correction to: Ubrogepant: First Approval
Correction to: Lonafarnib: First Approval
Correction to: Pexidartinib: First Approval
Correction to: Lenacapavir: First Approval
Correction to: Nedosiran: First Approval
Correction to: Triheptanoin: First Approval
Correction to: Ritlecitinib: First Approval
Correction to: Zavegepant: First Approval
Correction to: Sotorasib: First Approval
Correction to: Inclisiran: First Approval
Correction to: Tralokinumab: First Approval
Correction to: Spesolimab: First Approval